MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze to evaluate various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Major demo objectives have been To guage the safety and tolerability of

By clicking Submit, you admit that you may well be contacted by Fisher Scientific with reference for the comments you have got presented in this way. We won't share your details for some other needs. The information utilized to assistance the conclusions of the analyze can be obtained with th